Get started

Financials · MBOT

Microbot Medical Inc. (MBOT) financials

For the twelve months ended Jun 30, 2026, Microbot Medical Inc. reported -$16.34M of net income.

Net income, TTM
-$16.34M
Free cash flow, TTM
-$17.93M
Cash
$3.15M
Market cap
$73.9M
Annual net income-$13.14M
FY2016FY2025
Annual free cash flow-$13.11M
FY2016FY2025

MBOT revenue and earnings growth

MBOT revenueQ2 2026$241.0K

QoQ
+129.5%
FY YoY
-86.8%

MBOT revenue was $241.0K in fiscal Q2 2026 (ended Jun 30, 2026), up 129.5% from the prior quarter. For the full fiscal 2015 it was $116.9K, down 86.8% from fiscal 2014. It rose in 2 of the last 4 fiscal years.

MBOT net incomeQ2 2026-$5.63M

MBOT net income was -$5.63M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.50M a year earlier. For the full fiscal 2025 it was -$13.14M, compared with -$11.44M in fiscal 2024.

MBOT EPSQ2 2026-$0.08

MBOT diluted EPS was -$0.08 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.29.

MBOT free cash flowQ2 2026-$5.13M

MBOT free cash flow was -$5.13M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.58M a year earlier. For the full fiscal 2025 it was -$13.11M, compared with -$8.85M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Research and development$6.28M$6.63M$5.72M$7.74M$6.15M$3.40M$3.05M$2.52M$1.10M-$901.0K
Selling, general and admin$8.46M$5.00M$4.13M$5.54M$5.20M$5.69M$4.19M$4.73M$4.17M-$8.73M
Operating income-$14.74M-$11.63M-$9.86M-$13.28M-$11.36M-$9.09M-$7.24M-$7.24M$5.27M-$9.63M
Interest expense--------$237.0K$333.0K
Income tax-----$0$0---
Net income-$13.14M-$11.44M-$10.74M-$13.17M-$11.31M-$9.17M-$7.25M-$7.26M-$7.59M-$9.66M
EPS, basic-$0.29-$0.73-$1.05-$1.81-$1.59-$1.29-$1.70-$2.41-$2.76$5.92
EPS, diluted-$0.29-$0.73-$1.05-$1.81-$1.59-$1.29-$1.70-$2.41-$2.76$5.92
Diluted shares45.8M15.6M10.2M7.3M7.1M7.1M4.3M2.9M2.2M965,793.041

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$3.91M$3.11M$2.47M$2.44M$13.49M$19.65M$28.77M$5.24M$10.81M$2.71M
Short-term investments$74.68M$2.36M$3.92M$5.76M$2.00M$5.00M$2.52M---
Inventory$584.0K---------
Current assets$79.82M$5.82M$7.92M$8.81M$15.88M$25.25M$35.94M$5.83M$10.93M$3.31M
Total assets$81.54M$6.03M$8.33M$9.54M$16.77M$26.28M$37.13M$6.09M$11.02M$3.37M
Current liabilities$3.42M$2.46M$3.79M$2.07M$1.98M$1.34M$4.83M$4.76M$528.0K$783.0K
Total liabilities$3.99M$2.50M$3.83M$2.25M$2.39M$1.97M$5.59M$4.76M$556.0K$1.17M
Shareholders' equity$77.55M$3.53M$4.50M$7.29M$14.38M$24.31M$31.54M$1.33M$9.99M$1.70M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$13.05M-$8.83M-$8.53M-$11.55M-$9.35M-$7.25M-$6.45M-$5.31M-$4.86M-$786.0K
Capital expenditures$60.0K$25.0K$33.0K$84.0K$69.0K$91.0K$216.0K$223.0K$58.0K$25.0K
Free cash flow-$13.11M-$8.85M-$8.57M-$11.63M-$9.42M-$7.34M-$6.67M-$5.53M-$4.91M-$811.0K
Investing cash flow-$72.38M$1.54M$1.97M-$3.84M$3.20M-$2.77M-$2.45M-$223.0K-$58.0K-$25.0K
Financing cash flow$86.24M$7.94M$6.56M$4.32M--$3.38M$36.77M-$18.0K$13.02M$3.08M
Stock-based compensation$1.06M$1.35M$1.39M$1.75M$1.39M$1.94M$1.10M$1.40M$479.0K$676.0K
Depreciation and amortization$47.0K$91.0K$106.0K$102.0K$76.0K$68.0K$84.0K$54.0K--

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
EPS growth, YoY---------900.0%
Return on equity-16.9%-324.2%-238.6%-180.7%-78.7%-37.7%-23.0%-545.9%-76.0%-569.8%
Return on assets-16.1%-189.7%-129.0%-138.1%-67.5%-34.9%-19.5%-119.2%-68.9%-286.9%
Current ratio23.332.372.094.268.0018.787.451.2320.704.23

Source: XBRL data Microbot Medical Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported May 10, 2016; 5-for-74, first reported Nov 14, 2018.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

MBOT peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
MBOT---$16.34M-$73.9M
SYK$26.30B+7.9%$3.62B13.8%$124.00B
MMM$25.25B+1.7%$3.54B14.0%$97.47B
BSX$21.07B+8.9%$3.50B16.6%$63.81B
BDX$23.25B+17.4%$941.00M4.0%$58.63B
MDLN$30.68B-$683.00M2.2%$53.55B
RMD$5.73B+9.0%$1.59B27.8%$33.16B
DXCM$5.10B+13.0%$991.00M19.4%$30.24B
WST$3.40B+12.6%$638.90M18.8%$28.78B

MBOT FAQ

6 questions
  • Is MBOT profitable?
    No. Microbot Medical Inc. reported a net loss of $16.34M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does MBOT have?
    Microbot Medical Inc. reported $3.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is MBOT revenue growing?
    Microbot Medical Inc.'s revenue changed -86.8% in fiscal 2015, to $116.9K.
  • What is MBOT free cash flow?
    Microbot Medical Inc. generated -$17.93M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$17.64M less capital expenditures.
  • When did MBOT last report financial results?
    The latest statements here come from Microbot Medical Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this MBOT financial data come from?
    Quantisnow builds these statements from the structured XBRL data Microbot Medical Inc. files with the SEC. It is provided for information only and is not investment advice.